###### Strengths and limitations of this study

-   We comprehensively reviewed the global burden of herpes zoster.

-   We found a similar age-specific incidence of herpes zoster in North America, Europe and Asia-Pacific; however, there is a scarcity of research from other regions.

-   Because the quality of the study, study design and study population varied widely across studies, we could not synthesise the data quantitatively.

Introduction {#s1}
============

Herpes zoster (HZ), also known as shingles, is typically characterised by painful, blistering dermatomal rash.[@R1] [@R2] The estimated lifetime risk of HZ in the general population is approximately 30%, with the risk increasing sharply after 50 years of age.[@R3] After conducting a careful long-term observational study in the 1960s, Hope-Simpson[@R4] showed that HZ results from reactivation of the varicella-zoster virus (VZV) in sensory ganglia after a long latency period following primary infection from varicella (chickenpox). In some patients particularly in the elderly, the pain continues to persist after the rash heals and develops into postherpetic neuralgia (PHN), which is the most common complication. PHN causes physical disability, emotional distress and interference with daily activities and sleep.[@R5] HZ also causes neurological sequelae, HZ ophthalmicus (HZO) with eye involvement or disseminated disease. Severe cases of these complications often require hospitalisation.

A live-attenuated VZV vaccine (ZOSTAVAX by Merck) has been demonstrated to significantly reduce the incidences of HZ and PHN in addition to the severity and duration of pain associated with HZ.[@R6] Public health interventions that promote healthy ageing are increasingly becoming more important, as the elderly population is growing rapidly worldwide. Over the next half century, the proportion of people ≥60 years of age is projected to double, reaching more than 20% of the total population in all regions of the world.[@R7] Moreover, the prevalence of disability in the elderly populations is increasing across the world.[@R8]

It is essential for healthcare practitioners and health policymakers to be informed by the best available and up-to-date evidence on the HZ burden of disease. In a previous review by Thomas and Hall[@R9], there were limited population-based studies on HZ incidence. Since then, many studies have been conducted across countries to examine the incidence rates and temporal trends of HZ. Other reviews have been restricted to specific geographic regions.[@R10] [@R11] Moreover, to the best of our knowledge, there has been no systematic review of studies examining the risk of complications and hospitalisation. The objective of this study is to characterise the incidence rates of HZ and risk of complications across the world. We systematically reviewed studies examining the incidence rates of HZ, temporal trends of HZ, risk of HZ complications including PHN and HZ-associated hospitalisation and mortality rates in the general population.

Methods {#s2}
=======

Literature search {#s2a}
-----------------

We performed a literature search in PubMed, EMBASE, and the WHO\'s Global Health Library Regional Index up to December 2013. For PubMed, we used Medical Subject Headings (MeSH) and the title terms 'herpes zoster', 'zoster' or 'shingles' in combination with the term 'incidence'. We also searched eligible articles using MeSH and the title terms 'postherpetic neuralgia' or 'post-herpetic neuralgia'. We used the same search strategy with text terms in EMBASE and the WHO library. We manually searched the references cited by the retrieved articles and review articles for additional references. Two investigators (KK and BG) independently conducted a systematic review of the literature, assessed study eligibility and extracted data. Discrepancies were settled through discussion with a third investigator (CJA).

Inclusion and exclusion criteria {#s2b}
--------------------------------

We included studies examining the incidence of HZ, risk of PHN, risk of a recurrent episode of HZ, risk of HZO, HZ-associated hospitalisation or HZ-associated mortality. For studies examining the efficacy or effectiveness of vaccination against HZ, we included estimates of incidence rates among unvaccinated individuals. We did not apply language restrictions. We did not include studies limited to children, immunocompromised populations (eg, HIV, cancer and chronic kidney disease) or patients on immunosuppressive therapy (eg, corticosteroids). We also excluded review articles and case reports.

Data extraction {#s2c}
---------------

We developed a standard abstraction form for data extraction. We extracted information regarding authors, publication year, journal, country, study design, study year(s), population, number of cases, number at risk, case definition, case ascertainment, incidence rates of HZ (per 1000 person-years), risk of PHN and other complications, HZ-associated hospitalisation rates and HZ-associated mortality rates. For studies on incidence that did not report 95% CI, we computed exact 95% CI.

Results {#s3}
=======

After conducting a literature search, we included 130 studies conducted in 26 countries in this review ([figure 1](#BMJOPEN2014004833F1){ref-type="fig"}). There were 63 studies on the incidence of HZ from 22 countries[@R3] [@R4] [@R6] [@R12]; 25 studies on trends of HZ from 7 countries[@R3] [@R12] [@R15] [@R23] [@R27] [@R28] [@R49] [@R53] [@R65] [@R68] [@R72]; 60 studies on PHN from 19 countries[@R3] [@R4] [@R6] [@R12] [@R18] [@R33] [@R38] [@R40] [@R42] [@R43] [@R46] [@R54] [@R56] [@R60] [@R69] [@R81]; 9 studies on HZ recurrence from 5 countries[@R4] [@R12] [@R13] [@R57] [@R60] [@R119]; 12 studies on HZO from 5 countries[@R12] [@R35] [@R43] [@R61] [@R123]; 28 studies on hospitalisation rates from 14 countries[@R24] [@R26] [@R27] [@R30] [@R37] [@R41] [@R44] [@R46] [@R48] [@R52] [@R55] [@R56] [@R58] [@R62] [@R72] [@R73] [@R76] [@R77] [@R131] and 10 studies on mortality rates from 10 countries.[@R26] [@R30] [@R37] [@R41] [@R44] [@R48] [@R58] [@R62] [@R134] [@R138]
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Incidence rates of HZ {#s3a}
---------------------

Studies examining the incidence rates of HZ were conducted in countries from North America (N=18), Europe (N=33), Asia (N=7), South America (N=3) and the Middle East (N=2; [table 1](#BMJOPEN2014004833TB1){ref-type="table"}). The incidence rate of HZ ranged between 3 and 5/1000 person-years in North America, Europe and Asia-Pacific, based on studies using prospective surveillance, electronic medical record data or administrative data with medical record review. The age-specific incidence rates of HZ were similar across countries, with a steep rise after 50 years of age ([figure 2](#BMJOPEN2014004833F2){ref-type="fig"}). The incidence rate was about 6--8/1000 person-years at 60 years of age and 8--12/1000 person-years at 80 years of age. We observed an increase in the reported incidence rate over time within a country. For example, studies conducted more than 20 years ago in the USA by Ragozzino *et al*[@R12] and Donahue *et al*[@R13] showed lower rates compared with studies conducted in recent years. It is noteworthy that prospective population-based studies that identified relatively small numbers of patients with HZ (eg, by Scott *et al*,[@R33] Paul and Thiel,[@R39] Di Legami *et al*[@R55] and Lionis *et al*[@R59]) estimated lower incidence compared with other studies.

###### 

Incidence of HZ

  Country           Author               Study design and population                                                                            Case ascertainment                                           Year          HZ cases    Age         Incidence 1000 person- years   95% CI
  ----------------- -------------------- ------------------------------------------------------------------------------------------------------ ------------------------------------------------------------ ------------- ----------- ----------- ------------------------------ ----------------
  USA               Ragozzino            Medical records database in Minnesota                                                                  ICD-9 confirmed by medical records                           1945--1959    590         All ages    1.31                           1.15 to 1.35\*
  USA               Donahue              Health maintenance organisation claims database in Massachusetts                                       ICD-9 confirmed by medical records                           1990--1992    1075        All ages    2.15                           2.02 to 2.28\*
  USA               Insinga              MarketScan claims database in the USA                                                                  ICD-9                                                        2000--2001    9152        All ages    3.20                           3.10 to 3.20
  USA               Mullooly             Kaiser Northwest health maintenance organisation claims database                                       ICD-9 multiplied by positive predictive value                1997--2002    9895        All ages    3.69                           3.58 to 3.82
  USA               Yih                  Annual random-digit telephone survey in Massachusetts                                                  Survey from patients                                         1999--2003    194         All ages    4.33                           3.72 to 4.93\*
  USA               Jumaan               Health maintenance organisation claims database in Washington                                          ICD-9                                                        1992--2002    357         All ages    3.71                           
  USA               Oxman                Zostavax trial in the control group                                                                    Notified by physicians and PCR/culture confirmation          1998--2001    642         ≥60 years   11.12                          
  USA               Yawn                 Retrospective population-based study confirmed by medical records in Minnesota                         ICD-9 confirmed by medical records                           1996--2001    1669        ≥22 years   3.60                           3.40 to 3.70
  USA               Rimland              National Veterans Affairs claims database                                                              ICD-9                                                        2000--2007†   28 710      All ages    5.22                           
  USA               Leung                MarketScan claims database                                                                             ICD-9                                                        1993--2006†   48 000      All ages    4.40                           4.30 to 4.40
  USA               Tseng                Kaiser Southern California health maintenance organisation claims database in the unvaccinated group   ICD-9                                                        2007--2009    4606        ≥60 years   13.0                           12.6 to 13.3
  USA               Langan               Medicare claims database in the unvaccinated group                                                     ICD-9                                                        2007--2009    19 385      ≥65 years   15.1                           14.9 to 15.3
  USA               Chen                 Commercial, Medicare and Medicaid MarketScan claims database                                           ICD-9                                                        2005--2009    435 378     ≥18 years   4.82                           4.81 to 4.84
  USA               Hales                Medicare claims database                                                                               ICD-9                                                        1992--2010†   281 317     ≥65 years   14.2                           14.0 to 14.5
  Canada            Brisson              Administrative claims database in Manitoba                                                             ICD-9                                                        1979--1997†   NA          All ages    3.48                           
  Canada            Russell              Health insurance claims database in Alberta                                                            ICD-9/ICD-10                                                 1986--2002†   NA          All ages    4.30                           
  Canada            Edgar                Administrative claims database in British Columbia                                                     ICD-9                                                        1994--2003    114 596     All ages    2.89                           
  Canada            Tanuseputro          Administrative claims database in Ontario                                                              ICD-9                                                        1992--2010    686 763     All ages    3.23                           
  Canada            Russell              Health insurance claims database in Alberta                                                            ICD-9/ICD-10                                                 1994--2010†   213 265     All ages    4.50                           
  UK                Hope-Simpson         Prospective population-based study in Cirencester                                                      Medical records by GP                                        1947--1962    192         All ages    3.39                           
  UK                Ross                 Prospective population-based study in Glasgow                                                          Notified by 10 GPs                                           1972--1973    87          All ages    2.40                           
  UK                Brisson              RCGP database in England and Wales                                                                     ICD-9 medical records by GPs                                 1979--1997†   NA          All ages    3.82                           
  UK                Brisson              RCGP database in England and Wales                                                                     ICD-9 medical records by 69 GPs                              1991--2000    NA          All ages    3.73                           
  UK                Fleming              RCGP database in England and Wales                                                                     ICD-9 medical records by GPs                                 1994--2001†   14 532      All ages    3.90                           
  UK                Chapman              RCGP database in England and Wales                                                                     ICD-9 medical records by GPs                                 1994--2001    NA          ≥15 years   3.95                           
  UK                Scott                Prospective population-based study in East London                                                      Notified by 18 GPs and PCR confirmation                      NA            186         All ages    1.85                           
  UK                Gauthier             GPRD in UK                                                                                             Medical records by 603 GPs                                   2000--2006    27 225      ≥50 years   5.23                           5.17 to 5.29
  France            Chidiac              Prospective sentinel surveillance                                                                      Notified by 4635 GPs and 513 dermatologists                  1997--1998    8103        All ages    4.80                           
  France            Czernichow           Retrospective population-based study                                                                   Survey from 744 GPs                                          1998          605         All ages    3.20                           3.00 to 3.40
  France            Gonzalez- Chiappe    Prospective sentinel surveillance                                                                      Notified by 1200 GPs                                         2005--2008    2375        All ages    3.82                           3.64 to 4.05
  France            Mick                 Retrospective population-based study                                                                   Survey from 231 GPs, 41 dermatologists and 15 neurologists   2005          777         ≥50 years   8.99                           8.34 to 9.64
  Germany           Paul                 Prospective population-based study in Ansbach                                                          Notified by GPs, dermatologists and others                   1992--1993    152         All ages    2.26                           
  Germany           Schiffner-Rohe       National Statutory Health Insurance claims database                                                    ICD-10                                                       2004          1170        ≥50 years   9.80                           9.20 to 10.40
  Germany           Ultsch               National Statutory Health Insurance claims database                                                    ICD-10                                                       2007--2008    374 645     ≥50 years   9.60                           9.56 to 9.63
  Germany           Ultsch               National Statutory Health Insurance claims database                                                    ICD-10                                                       2004--2009    5384        All ages    5.79                           5.64 to 5.93
  The Netherlands   Opstelten            Huisartsen Netwerk Utrecht database in six locations                                                   Medical records from 22 GPs                                  1994--1999    837         All ages    3.40                           2.90 to 3.90
  The Netherlands   de Melker            Prospective sentinel surveillance                                                                      Notified by 43 GPs                                           1998--2001    NA          All ages    3.25                           
  The Netherlands   Opstelten            National survey of physicians                                                                          Medical records from 104 GPs                                 2001          1080        All ages    3.22                           3.00 to 3.40
  The Netherlands   Pierik               Retrospective population-based study in Almere                                                         Medical records from 22 GPs                                  2004--2008    3371        All ages    4.75                           4.06 to 5.44
  Switzerland       Richard              Prospective sentinel surveillance                                                                      Notified by 250 physicians                                   1998--2001    2236        All ages    2.36                           
  Belgium           Bilcke               Retrospective population-based study                                                                   Notified by 150 GPs                                          2000--2007    NA          All ages    3.78                           
  Spain             Pérez-Farinós        Prospective sentinel surveillance in Madrid                                                            Notified by GPs                                              1997--2004†   1798        All ages    3.59                           3.22 to 3.97
  Spain             García Cenoz         Primary care database in Navarre                                                                       Medical records from GPs                                     2005--2006    4959        All ages    4.15                           
  Spain             Cebrián-Cuenca       Prospective population-based study in Valencia                                                         Notified by 25 GPs                                           2006--2007    146         ≥14 years   4.10                           3.40 to 4.70
  Spain             Morant-Talamante     Electronic medical record database in Valencia                                                         ICD-9                                                        2007--2010    85 586      All ages    4.60                           4.57 to 4.63
  Spain             Esteban-Vasallo      Electronic medical record in the Madrid regional public health system                                  ICPC                                                         2005--2012†   211 650     All ages    4.82                           
  Italy             di Luzio Paparatti   Retrospective population-based study                                                                   Survey from 71 GPs                                           1995          408         ≥15 years   4.14                           3.75 to 4.56
  Italy             Di Legami            Prospective population-based study in Piedmont                                                         Notified by 24 GPs                                           2004          46          ≥14 years   1.74                           1.28 to 2.32
  Italy             Gialloreti           National primary-care database (Societa Italiana Medici Generici)                                      Medical records from 342 GPs                                 2003--2005    5675        All ages    4.31                           4.11 to 4.52
  Iceland           Helgason             Prospective population-based study                                                                     Notified by 62 GPs                                           1990--1995    462         All ages    2.00                           1.80 to 2.20
  Sweden            Studahl              Swedish National Pharmacy register                                                                     Prescriptions for antiviral medications                      2006--2010    127 832     All ages    2.70                           
  Greece            Lionis               Prospective population-based study in rural Crete                                                      Notified by 19 GPs                                           2007--2009    58          All ages    1.60                           
  Israel            Weitzman             Maccabi Healthcare Services claims database                                                            ICD-9                                                        2006--2010    28 977      All ages    3.46                           
  Saudi Arabia      Alakloby             Medical records from the dermatology clinic                                                            Medical charts from the dermatologist                        1988--2006    141         All ages    6.20                           5.18 to 7.22\*
  Australia         Stein                National GP database (Bettering the Evaluation of Care and Health)                                     Medical records of GPs                                       2000--2006    379         ≥50 years   9.67                           8.66 to 10.68
  Taiwan            Jih                  Taiwan National Health Insurance claims database                                                       ICD-9                                                        2000--2006    34 280      All ages    4.89                           4.76 to 5.04\*
  Taiwan            Lin                  Taiwan National Health Insurance claims database                                                       ICD-9                                                        2000--2005    672 782     All ages    4.97                           4.96 to 4.98
  Taiwan            Chao                 Taiwan National Health Insurance claims database                                                       ICD-9                                                        2000--2008    11 908      All ages    5.67                           
  South Korea       Park                 NA                                                                                                     NA                                                           1999--2003    1089        All ages    2.98                           
  South Korea       Choi                 Health Insurance claims database (estimated prevalence)                                                ICD-10                                                       2003--2007    2 431 744   All ages    9.97                           
  Japan             Toyama               Prospective population-based study in Miyazaki                                                         Notified by 46 dermatology clinics                           1997--2006    48 388      All ages    4.15                           4.12 to 4.19\*
  Argentina         Vujacich             Medical records from the ID reference centre                                                           Medical charts from IDs                                      2000--2005    302         All ages    3.57                           3.17 to 3.97\*
  Brazil            Castro               Medical records from the dermatology clinic                                                            Medical charts from the dermatologist                        1987--1989    469         All ages    5.62\*                         
  Colombia          Gaitan               Medical records from the oncology, radiology and nuclear medicine centre                               Medical charts from patients without cancer                  NA            75          NA          6.50\*                         

\*We computed the overall estimate or 95% CI based on the study results.

†The estimate from the latest study year.

GP, general practitioner; GPRD, general practice research database; HZ, herpes zoster; ICD, International Classification of Diseases; ICPC, International Classification For Primary Care; RCGP, Royal College of GPs.
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Trends of HZ incidence {#s3b}
----------------------

In the USA, studies conducted during the postvaricella vaccination era showed inconsistent results, with some showing no change in incidence but others reporting an increase in HZ incidence, suggesting a potential impact of varicella vaccination ([table 2](#BMJOPEN2014004833TB2){ref-type="table"}). However, Leung *et al*,[@R19] Hales *et al*[@R23] and Yawn *et al*[@R75] examined trends over a longer period and found that incidence rates increased continuously across all age groups before the introduction of the varicella vaccination programme and continued to increase throughout the postvaccination era. These studies concluded that the increase was not due to the varicella vaccination programme. Most studies conducted in Canada, the UK, Spain, Taiwan and Japan reported an increase in the incidence of HZ over the past decade often occurring in the absence of the national varicella vaccination programmes.[@R24] [@R25] [@R49] [@R65] [@R68] Several studies in Australia suggested increasing trends in HZ outpatient visits or hospitalisation during prevaricella and postvaricella vaccination eras.[@R76] [@R77] [@R79]

###### 

Temporal trends of herpes zoster

  Country     Author            Study periods   Varicella vaccination era   Trends
  ----------- ----------------- --------------- --------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------
  USA         Ragozzino         1945--1959      Pre                         Incidence increased from 1.1 to 1.5/1000 person-years between 1945--1949 and 1955--1959
  USA         Jumaan            1992--2002      Pre and post (1996--)       Incidence did not change between 1992 and 2002
  USA         Yih               1998--2003      Post                        Incidence increased from 2.8 to 5.3/1000 person-years between 1999 and 2003
  USA         Mullooly          1997--2002      Post                        Incidence did not change between 1997 and 2002
  USA         Yawn              1996--2005      Post                        Incidence increased from 3.2 to 4.1/1000 person-years between 1996--1997 and 2000--2001
  USA         Patel             1993--2004      Pre and post                Hospitalisation rate did not change during 1993--2000 but increased between 2001 and 2004
  USA         Jackson           1992--2004      Pre and post                Hospitalisation rate did not change during 1992--2004
  USA         Civen             2000--2006      Post                        Incidence increased between 2000 and 2006 among unvaccinated adolescents 10--19 years
  USA         Rimland           2000--2007      Post                        Incidence increased from 3.1 to 5.2/1000 person-years between 2000 and 2007
  USA         Yawn              1945--2008      Pre and post                Incidence increased from 0.8/1000 person-years in 1945--1947, to 1.6/1000 person-years in 1980--1982, to 3.0/1000 person-years in 2005--2007
  USA         Leung             1993--2006      Pre and post                Incidence increased from 1.7 to 4.4/1000 person-years between 1993 and 2006
  USA         Hales             1992--2010      Pre and post                Incidence increased from 10.0 to 13.9/1000 person-years between 1992 and 2010 in adults ≥65 years
  Canada      Brisson           1979--1997      Pre                         Incidence increased from 2.6 to 3.5/1000 person-years between 1979 and 1997
  Canada      Russell           1986--2002      Pre and post (2001--)       Incidence increased from 2.8 to 4.2/1000 person-years between 1986 and 2002
  Canada      Tanuseputro       1992--2010      Pre and post                Incidence did not change during 1992--2009
  Canada      Russell           1994--2010      Pre and post                Incidence increased from 3.5 to 4.5/1000 person-years between 1994 and 2010
  UK          Brisson           1979--1997      Pre                         Incidence increased from 3.2 to 3.9/1000 person-years between 1979 and 1997
  Spain       Perez-Farinos     1997--2004      Pre                         Incidence increased from 2.5 to 3.6/1000 person-years between 1997 and 2004
  Spain       Esteban-Vasallo   2005--2012      Pre and post (2006--)       Incidence increased from 3.6 to 4.8/1000 person-years between 2005 and 2012
  Australia   Macintyre         1993--1999      Pre                         Hospitalisation rate increased between 1993 and 1999
  Australia   Carville          1995--2007      Pre and post (2005--)       Hospitalisation rate increased from 6.3 to 9.1/100 000 person-years between 1995 and 2007
  Australia   Nelson            1998--2009      Pre and post                Incidence increased from 1.7 to 2.4/1000 person-years between 1998 and 2008
  Australia   Jardine           1998--2007      Pre and post                Hospitalisation rate did not change during 1992--2009
  Taiwan      Chao              2000--2008      Pre and post                Incidence increased from 4.5 to 6.9/1000 person-years between 2000 and 2008
  Taiwan      Wu                2000--2009      Pre and post                Incidence increased from 4.0 to 6.2/1000 person-years between 2000 and 2009
  Japan       Toyama            1997--2006      Low coverage (20--30%)      Incidence increased from 3.8 to 4.5/1000 person-years between 1997 and 2006

Risk of PHN {#s3c}
-----------

The risk of developing PHN varied from 5% to more than 30% ([table 3](#BMJOPEN2014004833TB3){ref-type="table"}; 49 studies). The estimated risk of PHN varied by study design, age distribution of study populations and definitions used for PHN. For studies that used multiple definitions of PHN, we present results based on the definition of at least 90 days of persistent pain. Studies that reported risk of PHN by age groups consistently found that older patients have a greater risk of developing PHN (see online supplementary table S1). In this review, we found that researchers have used a different duration of persistent pain (persisting for 30, 90 or 180 days) and severity of pain (clinically meaningful pain or any pain) to define PHN. For example, 18% of patients had pain for at least 30 days and 10% for at least 90 days in a population-based study using medical records by Yawn *et al*[@R3] in the USA. Similarly, 20% of patients had pain for at least 30 days and 14% for at least 90 days in a study by Gauthier *et al*[@R34] in the UK. Administrative database studies (eg, Ultsch *et al*[@R42] (4.5%), Opstelten *et al*[@R43] (2.6%) and Gialloreti *et al*[@R56] (6.2%)) were more likely to report a lower estimated risk of PHN compared with other studies. Researchers have used diagnosis and medication data in various algorithms, many of which are not validated. It is noteworthy that retrospective studies involving specialists (eg, Mick *et al*[@R38] (32.5%), Kanbayashi *et al*[@R102] (52%) and Ro *et al*[@R103] (39.4%)) may have included existing severe cases of patients with PHN and possibly overestimated the overall risk of PHN.

###### 

Risk of PHN in patients with herpes zoster

  Country                Author               Study design                                                                      Definition of PHN\*                                                             Year           PHN cases   Age         Risk of PHN (%)
  ---------------------- -------------------- --------------------------------------------------------------------------------- ------------------------------------------------------------------------------- -------------- ----------- ----------- -----------------
  USA                    Ragozzino            Medical records database in Minnesota                                             Physician diagnosis                                                             1945--1959     55          All ages    9.3
  USA                    Galil                Administrative claims database confirmed by medical records in Massachusetts      Pain persisted for ≥60 days from medical records                                1990--1992     68          All ages    7.9
  USA                    Oxman                Zostavax trial in the control                                                     Pain ≥3 score for ≥90 days                                                      1998--2001     80          ≥60 years   14.0
  USA                    Yawn                 Retrospective population-based study confirmed by medical records in Minnesota    Pain persisted for ≥90 days from medical records                                1996--2001     171         ≥22 years   10.0
  USA                    Thyregod             Prospective cohort study in California                                            Pain persisted for ≥180 days                                                    1999--2003     30          ≥50 years   31.9
  USA                    Klompas              Administrative claims database confirmed by medical records in Massachusetts      Pain persisted for ≥30 days and required pain medication from medical records   2008           237         ≥20 years   12.2
  USA                    Rimland              Atlanta Veterans Affairs claims database confirmed by medical records             Physician diagnosis from medical charts                                         2000--2007     205         All ages    19.6
  USA                    Katz                 Prospective cohort study in New York                                              Pain persisted for ≥120 days                                                    NA             20          ≥18 years   19.6
  Canada                 Drolet               Prospective cohort study, recruited by 83 physicians throughout country           Pain ≥3 score for ≥90 days                                                      2005--2006     56          ≥50 years   22.5
  UK                     Hope-Simpson         Prospective population-based study in Cirencester                                 Physician diagnosis                                                             1947--1962     46          All ages    14.3
  UK                     Scott                Prospective cohort study                                                          Pain persisted for ≥90 days                                                     NA             45          All ages    27.4
  UK                     Jung                 Prospective cohort study (combined two trials)                                    Pain persisted for ≥120 days                                                    NA             114         ≥15 years   12.8
  UK                     Scott                Prospective cohort study in East London                                           Pain persisted for ≥90 days                                                     NA             9           All ages    13.4
  UK                     Coen                 Prospective cohort study, recruited by GPs                                        Pain ≥3 score for ≥90 days                                                      1998--2001     24          All ages    9.0
  UK                     Gauthier             GPRD in the UK                                                                    Physician diagnosis or pain medication at 90 days from medical records          2000--2006     415         ≥50 years   13.7
  France                 Chidiac              Prospective sentinel surveillance                                                 Physician diagnosis                                                             1997--1998     935         All ages    10.3
  France                 Czernichow           Retrospective population-based survey from GPs                                    Pain persisted for ≥30 days and required treatment from medical records         1998           111         All ages    18.4
  France                 Mick                 Retrospective population-based survey from GPs, dermatologists and neurologists   Pain persisted for ≥90 days from medical records                                2005           227         ≥50 years   32.5
  France                 Bouhassira           Prospective cohort study, recruited by GPs                                        Pain persisted for ≥90 days                                                     2007--2008     127         ≥50 years   11.6
  Germany                Meister              Retrospective population-based survey from GPs, dermatologists and specialists    Pain persisted for ≥30 days and physician diagnosis                             NA             131         ≥50 years   20.6
  Germany                Schiffner-Rohe       National Statutory Health Insurance claims database                               Pain persisted for ≥90 days and diagnosis or pain medication from ICD-10        2004           NA          ≥50 years   6.9
  Germany                Weinke               Telephone survey of patients, previous HZ diagnosis in 5 years                    Pain persisted for ≥90 days                                                     2008           32          ≥50 years   11.4
  Germany                Ultsch               National Statutory Health Insurance claims database                               Pain persisted for ≥90 days and diagnosis or pain medication from ICD-10        2004--2009     18 160      All ages    4.5
  The Netherlands        Opstelten            Huisartsen Netwerk Utrecht database in six locations                              Pain persisted for ≥90 days and required treatment from medical records         1994--1999     22          All ages    2.6
  The Netherlands        Opstelten            Prospective cohort study, recruited by GPs (PINE trial)                           Pain ≥3 score for ≥90 days                                                      2001--2004     46          ≥50 years   7.1
  The Netherlands        Pierik               Population-based GPs database in Almere                                           Physician diagnosis from medical codes                                          2004--2008     195         All ages    5.8
  Spain                  Cebrian-Cuenca       Prospective cohort study, recruited by 25 GPs in Valencia                         Pain persisted for ≥90 days                                                     2006--2007     19          ≥14 years   14.5
  Spain                  Sicras Mainar        Medical records from six primary care and one hospital                            Physician diagnosis from medical records                                        2007--2010     228         ≥30 years   15.1
  Italy                  di Luzio Paparatti   Retrospective population-based survey from GPs                                    Pain persisted for ≥30 days from medical records                                1995           275         ≥15 years   19.6
  Italy                  Volpi                Prospective cohort study, recruited by dermatologists                             Pain ≥3 score for ≥180 days                                                     2001           70          NA          32.0
  Italy                  Parruti              Prospective cohort study, recruited from GPs and hospitals in Pescara             Pain persisted for ≥90 days                                                     2006--2008     130         NA          30.0
  Italy                  Gialloreti           National primary care database (Societa Italiana Medici Generici)                 Pain persisted for ≥90 days and diagnosis or pain medication from ICD-9         2003--2005     350         ≥50 years   6.2
  Italy                  Bricout              Prospective cohort study, recruited from GPs                                      Pain persisted for ≥90 days                                                     2009--2010     85          ≥50 years   20.6
  Iceland                Helgason             Prospective population-based study                                                Physician diagnosis at 90 days                                                  1990--1995     28          All ages    7.2
  6 European countries   Lukas                Telephone survey, previous 5 years                                                Pain persisted for ≥90 days                                                     2008----2009   131         ≥50 years   13.0
  Israel                 Weitzman             Maccabi Healthcare Services claims database                                       ICD-9 code and healthcare service code                                          2006--2010     1508        All ages    5.2
  Saudi Arabia           Alakloby             Medical record database from the dermatology clinic                               Physician diagnosis                                                             1988--2006     21          ≥18 years   14.9
  Australia              Stein                National GP database (Bettering the Evaluation of Care and Health)                Physician diagnosis from medical codes                                          2000--2006     57          ≥50 years   15.0
  Taiwan                 Jih                  Taiwan National Health Insurance claims database                                  Pain persisted for ≥90 days and diagnosis or pain medication from ICD-9         2000--2006     2944        All ages    8.6
  Taiwan                 Tsai                 Prospective cohort study in five centres                                          Pain ≥3 score for ≥90 days                                                      2008--2009     31          ≥50 years   20.7
  Japan                  Kurokawa             Prospective cohort study in hospitals and clinics in Hyogo                        Pain persisted for ≥90 days                                                     NA             37          ≥20 years   26.2
  Japan                  Kurokawa             Prospective cohort study in hospitals and clinics in Hyogo                        Pain persisted for ≥90 days                                                     2001--2003     78          All ages    24.7
  Japan                  Kanbayashi           Retrospective cohort study in pain treatment hospital                             Pain persisted for ≥90 days                                                     2008--2010     38          NA          52.0
  South Korea            Ro                   Retrospective, dermatology department hospital                                    NA                                                                              2007--2011     826         NA          39.4
  South Korea            Song                 Prospective cohort study in clinics                                               Pain ≥3 score for ≥90 days                                                      2009--2010     58          ≥50 years   38.4
  South Korea            Cho                  Prospective cohort study in clinics                                               Pain ≥3 score for ≥90 days                                                      2010--2012     19          ≥18 years   6.2
  Thailand               Tunsuriyawong        Retrospective study of medical records at hospital                                Physician diagnosis from medical record                                         1995--2000     67          All ages    16.8
  Thailand               Aunhachoke           Prospective cohort study, recruited by GPs                                        Pain persisted for ≥90 days                                                     2007--2008     35          ≥50 years   19.4
  Singapore              Goh                  Prospective cohort study in dermatology clinic                                    Pain persisted for ≥90 days                                                     1994--1995     46          All ages    28.0
  India                  Chaudhary            NA                                                                                NA                                                                              NA             33          NA          14.3
  India                  Abdul Latheef        NA                                                                                NA                                                                              NA             21          All ages    10.2
  Argentina              Vujacich             Medical record database from ID reference centre                                  Pain persisted for ≥60 days and diagnosis from medical records                  2000--2005     39          All ages    12.9
  Argentina              Vujacich             Prospective cohort study, recruited by GPs                                        Pain ≥3 score for ≥90 days                                                      NA             11          ≥50 years   11.5

\*For studies that used multiple definitions of PHN, we present results based on the definition that used at least 90 days of persistent pain.

GP, general practitioner; GPRD, general practice research database; HZ, herpes zoster; ICD, International Classification of Diseases; PHN, postherpetic neuralgia.

We identified six prospective cohort and three cross-sectional studies examining the duration of PHN in North America and Europe ([table 4](#BMJOPEN2014004833TB4){ref-type="table"}). Several studies reported that PHN may last up to 10 years. Prospective cohort studies demonstrated that approximately 30--50% of patients with PHN experienced pain lasting for more than 1 year. Cross-sectional studies also reported a similar high proportion of patients with PHN; however, these studies are most likely an overestimate because they are more likely to include patients experiencing a longer duration of pain.

###### 

Duration of postherpetic neuralgia (sorted by study design)

  Country                Author         Method                                            Population                                            Duration of PHN                                  
  ---------------------- -------------- ------------------------------------------------- ----------------------------------------------------- ------------------------------------------------ ----------------------
  USA                    Reda           A prospective cohort study of 8-year follow-up    14 patients with PHN with a median age of 65 years    Up to 4 years: 14%                               
  Canada                 Watson         A prospective cohort study of 11-year follow-up   156 patients with PHN with a median age of 71 years   1--11 years: 56%                                 
  UK                     Hope-Simpson   A prospective cohort study of 26-year follow-up   46 patients with PHN ≥60 years of age                 1--2 years: 7%                                   2--10 years: 22%
  UK                     McKendrick     A prospective cohort study of 9-year follow-up    158 patients with HZ ≥60 years of age                 21% of patients with HZ had pain for \>8 years   
  Iceland                Helgason       A prospective cohort study of 7-year follow-up    23 patients with PHN ≥60 years of age                 1--7 years: 35%                                  \>7 years: 17%
  France                 Bouhassira     A prospective cohort study of 1-year follow-up    127 patients with PHN ≥50 years of age                \>1 year: 50%                                    
  USA                    Oster          A cross-sectional study                           385 patients with PHN with a mean age of 77 years     1--2 years: 21%                                  2 to \>10 years: 46%
  UK                     Bowsher        A cross-sectional study                           39 patients with PHN with a mean age of 66 years      1--2 years: 21%                                  2 to \>10 years: 33%
  6 European countries   van Seventer   A cross-sectional study                           84 patients with PHN with a mean age of 71 years      \>1 years: 45%                                   

HZ, herpes zoster; PHN, postherpetic neuralgia.

Risk of recurrence {#s3d}
------------------

A limited number (N=9) of studies examined recurrence of HZ. Four studies reported a risk of \<1.5%, with three of these studies conducted over 1--2 years of follow-up.[@R13] [@R57] [@R119] [@R122] About 2.9% of patients had recurrence of HZ in Israel during 2 years of follow-up, while 2.3% of patients had recurrence in South Korea up to 10 years of obervation.[@R60] [@R121] However, studies with a long-term follow-up period tended to report a higher risk of recurrence. Hope-Simpson *et al*[@R115] reported that 4.7% had recurrence of HZ during 16 years of follow-up in the UK. Similarly, Ragozzino *et al*[@R12] reported that 5.3% of patients had episodes of recurrence during more than 20 years of follow-up. A recent study by Yawn *et al*[@R120] also demonstrated that a recurrence of HZ occurred with a rate of 6.2% after 8 years of follow-up. The risk of recurrence may also depend on immune status.[@R120] Thus, overall risk of recurrence may vary by inclusion of those immunocompromised individuals.

Risk of HZO {#s3e}
-----------

HZO occurs when VZV reactivation affects the distribution of the ophthalmic division of the trigeminal nerve and can occur with or without eye involvement. Although the number of population-based studies is limited, similar risks of HZO were reported across studies. The reported risks of HZO among patients with HZ were 10.1% (Ragozzino *et al*,[@R12] USA), 12.3% (Chidiac *et al*,[@R35] France), 14.4% (Opstelten *et al*,[@R43] the Netherlands) and 14.9% (Alakloby *et al*,[@R61] Saudi Arabia). Borkar *et al*[@R124] reported an overall incidence of 30.9/100 000 person-years, which corresponds to an approximately 10% risk among patients with HZ in the USA. As has been previously recognised, the risk of HZO is similar across age groups.[@R123] [@R124]

A wide range of eye complications, such as keratitis, uveitis and conjunctivitis, could result from HZO. The reported risk of these eye complications in patients with HZO ranged widely from approximately 30% to 78%.[@R125] In a population-based study in the USA, the risk of HZO with eye involvement among patients with HZ was 2.5%.[@R130] The HZ-associated eye complications required an average of 10 months of medical care with 6% of cases resulting in vision loss.[@R130]

Hospitalisation rates associated with HZ {#s3f}
----------------------------------------

We identified 28 studies that reported HZ-associated hospitalisation ([table 5](#BMJOPEN2014004833TB5){ref-type="table"}). All studies used hospital discharge or claims data. Rates of HZ-related hospitalisation ranged widely from 2 to 25/100 000 person-years in studies examining all ages. The variation in the estimates may reflect the differing admission criteria in the different settings. Hospitalisations with a primary diagnosis of HZ accounted for about 29--42% of HZ-related hospitalisations.[@R37] [@R62] [@R73] Studies that included hospitalisations with non-primary diagnosis codes (eg, secondary) may have overestimated the hospitalisation rate because they may represent prior or incidental HZ. Hospitalisation rates increased steeply with age, with the majority of the cases occurring in adults ≥50 years of age. For example, Jackson *et al*[@R73] reported HZ-associated hospitalisation rates (confirmed with medical records) ranging from 10/100 000 in adults 60--69 years of age to 65/100 000 in adults ≥80 years of age in the USA. Similarly, the rate of hospitalisation with primary diagnosis of HZ ranged from 13/100 000 in adults 60--64 years of age to 96/100 000 in adults ≥80 years of age in Australia.[@R62] The rates ranged from 31/100 000 in adults 60--64 years of age to 100/100 000 in adults ≥80 years of age in Germany.[@R41]

###### 

Hospitalisation rates associated with herpes zoster

  Country           Author              Study design/database                                 Case ascertainment                          Years        Age         Hospitalisation, 100 000 person-years   Older age group
  ----------------- ------------------- ----------------------------------------------------- ------------------------------------------- ------------ ----------- --------------------------------------- --------------------
  USA               Lin                 Hospital discharge data in Connecticut                ICD-9 primary or secondary                  1986--1995   All ages    16.1                                    144.2 in ≥80 years
  USA               Coplan              Kaiser Northern California                            ICD-9 primary confirmed by medical charts   1994         All ages    2.1                                     9.3 in ≥60 years
  USA               Patel               National inpatient sample data                        ICD-9 any diagnostic position               1993--2004   All ages    25.0                                    112.3 in ≥60 years
  USA               Jackson             Group Health in Washington medical records            ICD-9 primary confirmed by medical charts   1992--2004   ≥50 years   14.0                                    65.1 in ≥80 years
  Canada            Brisson             Hospital claims in Manitoba                           ICD-9 any diagnostic position               1979--1997   All ages    NA                                      86.0 in ≥65 years
  Canada            Edgar               Ministry of health service data in British Columbia   ICD-9/ICD-10 any diagnostic position        1994--2003   All ages    10.0                                    99.0 in ≥80 years
  Canada            Tanuseputro         Hospital discharge data in Ontario                    ICD-9/ICD-10 any diagnostic position        1992--2010   All ages    6.7                                     75.0 in ≥80 years
  UK                Brisson             Hospitalisation episode statistics in England         ICD-9/ICD-10 any diagnostic position        1995--1996   All ages    NA                                      148.0 in ≥65 years
  UK                Brisson             Hospitalisation episode statistics in England         ICD-10 primary diagnosis                    1991--2000   All ages    4.4                                     19.1 in ≥60 years
  France            Gonzalez- Chiappe   National hospital data                                ICD-10 primary diagnosis                    2005--2008   All ages    4.1                                     --
  Germany           Ultsch              Federal health monitoring system                      ICD-10 primary diagnosis                    2007--2008   ≥50 years   44.6                                    102.5 in ≥80 years
  The Netherlands   de Melker           National healthcare registry                          ICD-9/ICD-10 primary or secondary           1998--2001   All ages    2.7                                     19.0 in ≥80 years
  The Netherlands   Pierik              Retrospective population-based study, GPs in Almere   Hospital referrals by GPs                   2004--2008   All ages    15.5                                    --
  Belgium           Bilcke              National Christian Sickness Fund                      ICD-9 primary or secondary                  2000--2007   All ages    14.2                                    85.0 in ≥80 years
  Spain             Gil                 National hospital data                                ICD-9 any diagnostic position               1999--2000   All ages    8.4                                     --
  Spain             Gil                 National hospital data                                ICD-9 primary or secondary                  1998--2004   ≥30 years   13.4                                    54.3 in ≥80 years
  Spain             Bayas               National hospital data in Catalonia                   ICD-9 any diagnostic position               1993--2003   All ages    9.7                                     --
  Spain             Morant- Talamante   Electronic medical record database in Valencia        ICD-9 any diagnostic position               2007--2010   All ages    3.0                                     15.7 in ≥80 years
  Spain             Gil-Prieto          National hospital data                                ICD-9 any diagnostic position               2005--2010   All ages    10.3                                    --
  Italy             Di Legami           Hospital discharge records in Piemonte                ICD-9 primary or secondary                  2004         ≥14 years   12.0                                    46.0 in ≥80 years
  Italy             Gialloreti          National hospital discharge records                   ICD-9 primary diagnosis                     2003--2005   All ages    5.6                                     26.0 in ≥80 years
  Portugal          Mesquita            National public hospital data                         ICD-9 primary diagnosis                     2000--2010   All ages    1.9                                     --
  Sweden            Studahl             National patient register                             ICD-10 primary diagnosis                    2006--2010   All ages    6.9                                     --
  Australia         MacIntyre           National hospital morbidity data                      ICD-9/ICD-10 any diagnostic position        1998--1999   All ages    25.0                                    300.0 in ≥80 years
  Australia         Stein               National hospital morbidity data                      ICD-10 primary diagnosis                    1998--2005   ≥50 years   28.0                                    95.8 in ≥80 years
  Australia         Carville            Victoria admitted episode data                        ICD-10 primary diagnosis                    2006--2007   All ages    9.1                                     89.4 in ≥80 years
  Taiwan            Jih                 National health insurance registry                    ICD-9                                       2000--2006   All ages    16.1                                    100.0 in ≥80 years
  Taiwan            Lin                 National health insurance registry                    ICD-9                                       2000--2005   All ages    14.6                                    --

GP, general practitioner; ICD, International Classification of Diseases.

Mortality rates associated with HZ {#s3g}
----------------------------------

Mortality rates associated with HZ ranged from 0.017 to 0.465/100 000 person-years in studies (see online supplementary table S2). Most studies reported that the majority of deaths occurred in adults ≥60 years of age.

Discussion {#s4}
==========

HZ is a significant global health burden that is expected to increase as the population ages. The incidence rises steeply after 50 years of age and many working-age adults and elderly individuals are at increased risk. Risk of complications, particularly debilitating and long-lasting PHN, and hospitalisation is common in the elderly population. The major strength of our study is that we assessed the HZ burden across the globe and comprehensively reviewed incidence, risk of complications, hospitalisation and mortality. Our review included 63 studies on incidence, substantially more than the prior review by Thomas and Hall,[@R9] which included 17 studies with overall incidence ranging from 1.2 to 4.8/1000 person-years. Other reviews were restricted to specific geographic regions and/or assessed only incidence.[@R10] [@R11]

Relatively similar estimates of the HZ incidence rate (between 3 and 5/1000 person-years) were reported in North America, Europe and Asia-Pacific. However, we observed some variations in estimates most likely due to the various study designs, case ascertainments, age distributions of the population and year of the study. It is difficult to accurately estimate the incidence rates because it is not a commonly reportable disease and surveillance systems are not usually in place. Most studies had limitations in their study methodology. Almost all studies may be susceptible to under-reporting due to patients who did not seek medical care. However, administrative database studies using diagnostic and billing codes may have overestimated the incidence due to misclassification. Several validation studies reported a relatively high sensitivity for the International Classification of Diseases (ICD)-9 code (98%) and positive predictive value (PPV; 84--94%).[@R15] [@R83] [@R139] Furthermore, studies using administrative insurance data may lack generalisability because they may not be representative of the general population. Population-based surveillance studies face difficulty in estimating the numbers of the population at risk in the study catchment area. Several prospective cohort studies that identified relatively small numbers of patients with HZ (eg, by Scott *et al*, Paul and Thiel, Di Legami *et al* and Lionis *et al*) may have underestimated the rate of HZ due to under-reporting of cases or inaccuracy in estimating the numbers of the population at risk. In spite of these limitations, it is reassuring to find similar incidences across countries in well-conducted studies.

There is a scarcity of research examining the incidence of HZ in Asia, Latin America and Africa. HZ may be regarded as a low health priority in many of these countries; however, the proportion of people ≥60 years of age is projected to double in the next several decades, and the numbers of HZ cases are expected to increase substantially. Further research is needed because it is unclear whether the incidence would be similar in these regions. Age-specific incidence rates may vary because of the regional differences in epidemiology of varicella infection and VZV genotype distribution. Varicella primarily affects young children in temperate countries, whereas varicella tends to occur at a later age during adolescence and adulthood, presenting in severe form with frequent risks of complication and mortality in tropical countries.[@R140] [@R141] Severe varicella infections during adolescence may result in greater numbers of VZVs remaining latent and possibly resulting in earlier reactivation of VZV.[@R142] The distribution of VZV clades varies globally.[@R143] [@R144] VZV can be classified into at least five major clades. VZV clades 1 and 3 are dominant strains in Europe and the Americas, whereas clade 2 is a dominant strain in Asia and clade 5 in Africa.[@R143] Molecular epidemiology of VZV is still an active area of investigation and requires more research. Furthermore, the incidence of HZ may be higher in the countries heavily affected by HIV/AIDS or other immunocompromising conditions.

Hope-Simpson[@R4] hypothesised that exogenous exposure to VZV from individuals with varicella or HZ may boost VZV-specific cell-mediated immunity and thereby decrease the risk of HZ. Because varicella vaccination programmes reduce VZV circulating in the community, thus potentially leading to a decrease in the opportunity for boosting immunity against VZV, it has been hypothesised that the introduction of varicella vaccination might increase the incidence of HZ in the population. However, based on the current literature, there is no conclusive evidence as to whether varicella vaccination programmes have been associated with an increase in the incidence of HZ. In fact, a number of studies across countries have found an increase in the incidence of HZ before introduction of the varicella vaccination programme. It is unclear why the incidence of HZ is increasing. The temporal change or emergence of infectious disease is usually due to changes in the society, technology, virus itself or environment, such as climate change.[@R145] The temporal increase was independent of age. It may partly be explained by an increase in the prevalence of risk factors, an increase in the use of immunosuppressive agents (eg, chemotherapy) or an increase in diagnosis through improved access to healthcare and public awareness. Because HZ is usually clinically diagnosed, diagnostic modalities are unlikely to have affected the reported incidences. Given the steady continuous increase in the incidence of HZ across age groups, it is plausible that a genetic change in the VZV may be playing a role. For example, a study in the UK suggested that changes in genotype distribution have occurred through importation of different strains.[@R146] Although VZV is considered a genetically stable virus, a recombination between different VZV strains could possibly occur.[@R143] [@R147]

We reviewed the risk of PHN in patients with HZ. Several long-term prospective cohort studies demonstrated that more than 30% of patients with PHN could experience pain lasting for more than 1 year. The reported risk of developing PHN in patients with HZ varied widely from 5% to more than 30%. The risk of PHN may have differed across countries due to the varying prevalence of disability and other underlying comorbidities in the elderly population.[@R8] [@R148] However, we could not conclude whether the risk of PHN differed by country because of wide variation. The wide variation in the estimates could be partly due to the different study designs used in prior studies. Prospective cohort studies of patients with HZ tend to report greater risk of PHN than studies utilising electronic medical records or administrative databases. We found that administrative database studies often face a numbers of challenges in identifying patients with PHN and they are likely to underestimate the risk of PHN. Currently, there is only one study, by Klompas *et al*,[@R83] that developed and validated an algorithm for PHN using ICD-9 codes and claims for a filled prescription. The algorithm detected PHN with a sensitivity of 86% and PPV of 78%; however, they defined PHN as a persistent pain for 30 days or more after zoster onset rather than 90 days or more. More validation studies are needed.

Researchers used different definitions of PHN. A difficulty in reaching consensus on a definition for PHN is probably due to a multifactorial pathophysiological nature of the condition and difficulty in objectively assessing the pain.[@R149] Patients with PHN also experience different types of pain including a steady burning pain, a sudden stabbing pain or stimulus-evoked pain (allodynia). The best option for defining PHN would be clinically meaningful pain lasting for more than 90 days after rash onset, considering the pathophysiology and definitions suggested from prior trials on antiviral treatment and zoster vaccination.[@R6] [@R150] [@R151] We also believe that healthcare utilisation patterns and prescribed treatment for PHN vary across countries and that characterising the treatment patterns would be important for future research.

Several prior studies with a long-term follow-up found that recurrence of HZ is frequent, with a rate of 5--6%, which is comparable to rates of first occurrence of HZ. However, a limited number of studies examined the risk of recurrence and more studies are needed to confirm these findings. There were a limited number of population-based studies examining HZO, a severe condition that may lead to significant visual impairment.

Several limitations of this review are worth noting. Because the quality of the study, study design and age distribution of population varied widely across studies, we could not synthesise the data quantitatively to estimate the pooled incidence rates. We did not conduct a formal study quality assessment. However, we described the study design and outcome ascertainment of each study and discussed limitations of studies. Our review focused on general populations, primarily immunocompetent populations, and we did not include studies restricted to immunocompromised populations (such as HIV/AIDS, malignancy or autoimmune disease). Our review also did not include uncommon complications of HZ, such as Ramsay Hunt syndrome, Bell\'s palsy and transverse myelitis.

In conclusion, similar age-specific incidence of HZ was reported in North America, Europe and Asia-Pacific; however, there is a scarcity of research from other regions. Risk of complications, particularly PHN, and hospitalisation is common in the elderly population. HZ is a global health burden that is expected to increase as the population ages across the world in the near future. The prevalence of disability in the elderly populations is also increasing. It is important for healthcare practitioners and health policymakers to consider implementing effective preventive measures such as vaccination against HZ across the globe.
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